2013
DOI: 10.1111/j.1365-4632.2011.05320.x
|View full text |Cite
|
Sign up to set email alerts
|

Ustekinumab for the treatment of nail psoriasis in heavily treated psoriatic patients

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1
1

Citation Types

0
17
0

Year Published

2013
2013
2020
2020

Publication Types

Select...
7
3

Relationship

1
9

Authors

Journals

citations
Cited by 30 publications
(17 citation statements)
references
References 10 publications
(24 reference statements)
0
17
0
Order By: Relevance
“…[99100] Recently, Patsatsi et al .,[99] conducted an open-label study to evaluate the role of ustekinumab in the treatment of nail psoriasis. Twenty-seven patients were taken and scheduled to receive subcutaneous injections of ustekinumab at a dose of 45 mg at baseline and week 4 and every 12 weeks.…”
Section: Treatment Of Nail Psoriasismentioning
confidence: 99%
“…[99100] Recently, Patsatsi et al .,[99] conducted an open-label study to evaluate the role of ustekinumab in the treatment of nail psoriasis. Twenty-seven patients were taken and scheduled to receive subcutaneous injections of ustekinumab at a dose of 45 mg at baseline and week 4 and every 12 weeks.…”
Section: Treatment Of Nail Psoriasismentioning
confidence: 99%
“…Ustekinumab, an anti-IL-12/23 monoclonal antibody, was highly effective in treating nail psoriasis, when weight-based dosing was used 36,37,38,39,40 . Limited data show that IL-17 blockade with ixekinumab (> 75 mg subcutaneously) also appears to be effective 41 .…”
Section: Journal Of Rheumatologymentioning
confidence: 99%
“…Two patients treated in combination with cyclosporine 100 mg b.i.d. had complete resolution of their nail psoriasis at week 12 [67]. After longer term safety and efficacy are proven, ustekinumab could become an effective option for treatment of nail psoriasis.…”
Section: Biologic Treatmentsmentioning
confidence: 99%